Biosion, Inc

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion

Interest in the anti-TSLP space continued on 16 May with Johnson & Johnson agreeing to pay $850m up front to acquire privately held Proteologix Inc. and its pipeline of bispecific antibodies, led

Competition to Amgen, Inc. and AstraZeneca PLC ’s anti-TSLP drug Tezspire (tezepelumab) is growing as Uniquity Bio moved out of stealth on 15 May with $300m from sole investor Blackstone and its

Multiple Chinese developers of antibody-drug conjugates (ADCs) are now turning their focus to bispecific candidates based on different target combinations as they look to diversify their expertise in